ALNYLAM PHARMACEUTICALS ($ALNY) posted quarterly earnings results for Q1 2026 on Thursday, April 30th. The company reported earnings of $1.99 per share, beating estimates of $0.95 by $1.04. The company also reported revenue of $1,167,180,000, beating estimates of $1,135,950,478 by $31,229,522.
You can see Quiver Quantitative's $ALNY stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ALNYLAM PHARMACEUTICALS Insider Trading Activity
ALNYLAM PHARMACEUTICALS insiders have traded $ALNY stock on the open market 273 times in the past 6 months. Of those trades, 0 have been purchases and 273 have been sales.
Here’s a breakdown of recent trading of $ALNY stock by insiders over the last 6 months:
- YVONNE GREENSTREET (Chief Executive Officer) has made 0 purchases and 60 sales selling 51,917 shares for an estimated $20,420,981.
- KEVIN JOSEPH FITZGERALD (CSO & EVP, Head of Research) has made 0 purchases and 66 sales selling 24,469 shares for an estimated $9,634,419.
- PUSHKAL GARG (EVP Chief R&D) has made 0 purchases and 53 sales selling 16,584 shares for an estimated $5,431,156.
- JEFFREY V. POULTON (EVP, Chief Financial Officer) has made 0 purchases and 40 sales selling 9,696 shares for an estimated $3,224,118.
- TOLGA TANGULER (EVP, Chief Commercial Officer) has made 0 purchases and 40 sales selling 7,376 shares for an estimated $2,424,943.
- MELISSA MCLAUGHLIN (Chief Human Resources Officer) has made 0 purchases and 14 sales selling 3,910 shares for an estimated $1,274,342.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
ALNYLAM PHARMACEUTICALS Hedge Fund Activity
We have seen 418 institutional investors add shares of ALNYLAM PHARMACEUTICALS stock to their portfolio, and 427 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 2,181,890 shares (-77.0%) from their portfolio in Q4 2025, for an estimated $867,628,558
- REGENERON PHARMACEUTICALS, INC. removed 1,392,303 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $553,649,287
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,022,637 shares (-47.0%) from their portfolio in Q4 2025, for an estimated $406,651,603
- FMR LLC removed 865,476 shares (-5.2%) from their portfolio in Q4 2025, for an estimated $344,156,531
- BANK OF AMERICA CORP /DE/ removed 813,314 shares (-54.3%) from their portfolio in Q4 2025, for an estimated $323,414,312
- INVESCO LTD. added 683,998 shares (+46.2%) to their portfolio in Q4 2025, for an estimated $271,991,804
- JANE STREET GROUP, LLC removed 647,462 shares (-67.5%) from their portfolio in Q4 2025, for an estimated $257,463,264
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
ALNYLAM PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $ALNY in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- B of A Securities issued a "Buy" rating on 01/30/2026
- Barclays issued a "Overweight" rating on 01/28/2026
- Needham issued a "Buy" rating on 01/12/2026
- Truist Securities issued a "Buy" rating on 01/08/2026
- Stifel issued a "Buy" rating on 12/11/2025
To track analyst ratings and price targets for ALNYLAM PHARMACEUTICALS, check out Quiver Quantitative's $ALNY forecast page.
ALNYLAM PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $ALNY recently. We have seen 14 analysts offer price targets for $ALNY in the last 6 months, with a median target of $445.5.
Here are some recent targets:
- Danielle Brill from Truist Securities set a target price of $505.0 on 04/13/2026
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $510.0 on 03/25/2026
- Keay Nakae from Chardan Capital set a target price of $425.0 on 03/25/2026
- Faisal Khurshid from Jefferies set a target price of $330.0 on 03/16/2026
- Whitney Ijem from Canaccord Genuity set a target price of $429.0 on 02/17/2026
- Ilya Zubkov from Freedom Capital Markets set a target price of $410.0 on 02/17/2026
- Joseph Stringer from Needham set a target price of $510.0 on 02/12/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
